Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001580232 | SCV001809869 | likely pathogenic | Glanzmann thrombasthenia | 2024-09-05 | reviewed by expert panel | curation | The p.Asn365Ser missense variant on ITGB3 gene has been previously reported in the context of Glanzmann thrombasthenia. The highest population minor allele frequency in gnomAD v4.1 is 0.000001695 (2/1179950 alleles) in the European non-Finnish population, which is lower than the ClinGen PD VCEP threshold (<0.0001; PM2_Supporting). This variant has been reported to occur in compound heterozygous state with a pathogenic frameshift variant (p.Gln508Serfs*) in one proband (PM3_supporting) who meets the PD-VCEP criteria for the GT phenotype (PMID: 25728920). The patient presented with significant mucocutaneous bleeding. Platelet aggregometry demonstrated absence of platelet aggregation with 3 platelet agonists and normal aggregation with ristocetin. Surface expression of αIIbβ3 was demonstrated to be reduced (<5%) by flowcytometry (PMID: 25728920); PP4_strong). Multiple in silico tools predict this variant to be deleterious (REVEL score = 0.94). This variant meets GT specific criteria for PP4_Strong, PM3_supporting, PP3 and PM2_supporting and is therefore classified as Likely Pathogenic. |